Ipamorelin: The Selective Growth Hormone Secretagogue

Ipamorelin is a synthetic pentapeptide, a short chain of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2), classed as a growth hormone secretagogue. Rather than supplying GH directly, it prompts the pituitary gland to release more of the body’s own. It was first described by Raun and colleagues in a 1998 paper in the European Journal of Endocrinology, which gave it the label that still defines it: “the first selective growth hormone secretagogue.”

It belongs to the same broad family as CJC-1295 and sermorelin, though it works through a different receptor, which is why the three are often discussed together in growth-hormone contexts. It is marketed almost everywhere online as a “research use only” chemical, a phrasing that reflects its lack of approval rather than any endorsed human use.

The bottom line: Ipamorelin is a five-amino-acid peptide designed to stimulate natural GH release, originally developed in the late 1990s and never brought to market as an approved drug.

Ipamorelin works by binding to and activating the growth hormone secretagogue receptor, subtype 1a (GHS-R1a), in the pituitary gland. This is the same receptor activated by ghrelin, the body’s natural “hunger hormone,” which is why ipamorelin is often called a ghrelin mimetic. Activating GHS-R1a, a G-protein-coupled receptor, sets off intracellular signalling (including a rise in cyclic AMP) that produces a pulse of GH release.

The feature that made ipamorelin scientifically interesting is its selectivity. Earlier growth-hormone-releasing peptides such as GHRP-6 and hexarelin also raise GH, but they tend to raise cortisol, prolactin, and ACTH at the same time. In the original animal work, ipamorelin released GH without meaningfully elevating those other hormones, giving it a “cleaner” profile closer to that of natural growth-hormone-releasing hormone (GHRH). It also tends to preserve the pulsatile rhythm of GH secretion rather than forcing a flat, continuous elevation.

The bottom line: Ipamorelin activates the ghrelin receptor to release GH in natural pulses while largely sparing cortisol and prolactin, which is what “selective” means in its case.

The honest summary is that ipamorelin’s evidence base is thin and heavily weighted toward animal studies. This is the most important and most frequently misrepresented fact about the compound, so it is worth being precise about evidence tiers.

• Preclinical (animal) data: The large majority of what is known about ipamorelin comes from rodent and other animal models, including its original characterisation and later work on GH release and gastrointestinal motility.
• Early human pharmacology: A small number of pharmacokinetic and pharmacodynamic studies in humans confirmed that ipamorelin does raise GH after administration, establishing the mechanism in people.
• Clinical efficacy trials: The drug was investigated commercially and advanced into a Phase 2 trial for postoperative ileus (slowed gut function after surgery), but that programme did not succeed and development was discontinued. There are no completed human trials establishing efficacy for the body-composition, anti-ageing, or growth-hormone-deficiency uses it is marketed for online.

In other words, the claim that “ipamorelin raises GH” is well supported. The much larger claims that it reliably improves muscle, fat loss, recovery, or ageing outcomes in humans are not supported by completed clinical trials. Treating animal and mechanistic data as if it were proof of human benefit is the central error to avoid here.

The bottom line: Ipamorelin’s mechanism is proven in humans, but its real-world benefits are supported only by animal data and a discontinued clinical programme, never by a successful human efficacy trial.

Ipamorelin has no marketing approval in any major jurisdiction, and in the United States it currently cannot be legally used in pharmacy compounding either.

United States: the compounding timeline

In September 2023, ipamorelin acetate was placed into Category 2 of the FDA’s interim 503A bulks list. After compounding-industry litigation (the Evexias and Farmakeio case), the nomination supporting ipamorelin was withdrawn, and the FDA removed it from Category 2 in late September 2024 while referring it to its expert advisory panel. On 29 October 2024, the Pharmacy Compounding Advisory Committee (PCAC) voted against adding ipamorelin to the 503A bulks list, alongside ibutamoren, L-theanine, and kisspeptin-10. The committee’s stated reasons centred on insufficient human safety and efficacy data. That anamorelin – a closely related ghrelin-receptor agonist – has been approved in Japan for cancer cachexia illustrates the evidence bar ipamorelin has not cleared: a compound acting on the same receptor can reach approval when the clinical data supports it. For how the category system works, see our explainer on FDA Category 1 vs Category 2.

UK and Australia

In the UK, ipamorelin holds no MHRA marketing authorisation and is not a licensed medicine. In Australia it is not on the Australian Register of Therapeutic Goods, and GH secretagogues fall within prescription-only territory under the TGA framework. In both countries it is sold only as a “research” chemical rather than as an approved treatment.

Region	Regulator	Status
United States	FDA	Not approved; PCAC voted against compounding
United Kingdom	MHRA	No marketing authorisation; not a licensed medicine
Australia	TGA	Not on the ARTG; prescription-only class
Sport	WADA	Prohibited at all times (class S2)

As a growth hormone secretagogue, ipamorelin is on the World Anti-Doping Agency’s Prohibited List (category S2) and is banned in tested sport at all times, in and out of competition. For the full country-level detail see our guides to US peptide legality, UK peptide legality, and Australian peptide law.

The bottom line: Ipamorelin is unapproved in the US, UK, and Australia, cannot currently be compounded in the US following the PCAC vote against it, and is banned in tested sport.

Reported side effects in the limited human pharmacology data and class experience tend to be mild and short-lived: headache, dizziness, flushing or a warm sensation, injection-site reactions, and occasional water retention. Because ipamorelin largely avoids the off-target hormones, it is associated with less appetite stimulation and less cortisol and prolactin disturbance than older GHRPs.

The more serious concerns are structural rather than anecdotal. First, raising GH and the downstream hormone IGF-1 carries theoretical risks, including effects on insulin sensitivity and blood sugar, fluid retention, and concerns around cell growth that apply to the whole class. Second, and more practically, the FDA advisory committee’s central objection in 2024 was the absence of robust human safety data, meaning the long-term consequences of sustained use simply have not been characterised in proper trials. Third, because the product is unapproved, real-world risk is dominated by what is actually in the vial: gray-market peptides routinely vary in purity and dose and can carry contaminants, none of which is detectable without independent testing.

The bottom line: Short-term side effects appear mild, but the real risk profile is defined by missing long-term human data and the unverified quality of unapproved product.

Ipamorelin is frequently discussed alongside other growth-hormone-axis compounds because they are often grouped or stacked. It is worth understanding how it differs from its closest relatives.

• CJC-1295 and sermorelin act on the growth-hormone-releasing hormone (GHRH) receptor, a different pathway from ipamorelin’s ghrelin receptor. They are commonly paired with secretagogues because the two mechanisms are complementary. See our CJC-1295 vs sermorelin comparison for that distinction.
• MK-677 (ibutamoren) is an orally active ghrelin-receptor secretagogue that works on the same receptor as ipamorelin but is taken as a tablet and produces a more sustained effect. It was reviewed and rejected at the same PCAC meeting. Our ipamorelin vs MK-677 comparison covers the trade-offs.
• Anamorelin is a closely related ghrelin-receptor agonist that has actually been approved in Japan for cancer-related cachexia, which usefully demonstrates that this receptor target can yield a genuinely approved drug when the clinical evidence is developed.

The wider regulatory story is still moving. Reclassification of several previously restricted peptides has been raised publicly at federal level, but as announced it has not been formally enacted. We track that separately in our peptide reclassification tracker. And because ipamorelin is sold exclusively through unregulated channels, anyone researching suppliers should first read our guide on vetting a peptide supplier.

The bottom line: Ipamorelin is one node in a cluster of growth-hormone compounds, and its nearest approved relative, anamorelin, shows the bar of evidence that ipamorelin itself has not yet cleared.